AstraZeneca Fourth Quarter and Full Year Results 2009 |
| Friday, 29 January 2010 |
|
|
Friday, February 5, 2010
AstraZeneca Fourth Quarter and Full Year Results 2009
Revenue in the fourth quarter increased by 4 percent at constant exchange rates (CER), but was up 9 percent on an actual basis as a result of the positive impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); 
Subscribe to:
Post Comments (Atom)
AstraZeneca Fourth Quarter and Full Year Results 2009 |
| Friday, 29 January 2010 |
|
|
No comments:
Post a Comment